We examined plasma levels of the sympathetic neurotransmitter norepinephrine (NE) and its deaminated metabolite dihydroxyphenylglycol (DHPG) during supine rest in healthy human subjects and in sympathectomized patients, during physiological (tilt) or pharmacological (yohimbine, clonidine) manipulations known to affect sympathetically mediated NE release, during blockade of neuronal uptake of NE (uptake-i) using desipramine, and during intravenous infusion of NE. Healthy subjects had a mean arteriovenous increment in plasma DHPG in the arm (10%, P < 0.05), whereas sympathectomized patients had a mean arteriovenous decrement in DHPG in the affected limb (mean decrease 21%, P < 0.05 compared with healthy subjects). Tilt and yohimbine, which stimulate, and clonidine, which inhibits, release of endogenous NE, produced highly correlated changes in plasma NE and DHPG (r = 0.94). Pretreatment with desipramine abolished DHPG responses to yohimbine while enhancing NE responses. To attain a given increase in plasma DHPG, about a tenfold larger increment in arterial NE was required during NE infusion than during release of endogenous NE. When plasma NE was markedly suppressed after administration of clonidine, plasma DHPG decreased to a plateau level of 700-800 pg/ml. The results indicate that (i) plasma DHPG in humans is derived mainly from sympathetic nerves; (ii) increments in plasma DHPG during stimulation of NE release result from uptake of NE into sympathetic nerve endings and subsequent intraneuronal conversion to DHPG; (ii) plasma DHPG under basal conditions probably is determined mainly by net leakage of NE into the axonal cytoplasm from storage vesicles; and (iv) increments in NE concentrations at neuronal uptake sites can be estimated by simultaneous measurements of DHPG and NE during NE infusion and NE release. Measurement of NE and DHPG provides unique clinical information about sympathetic function.
Introduction
Dihydroxyphenylglycol (DHPG)1 is a deaminated metabolite of the sympathetic neurotransmitter norepinephrine (NE).
Results of in vitro studies and studies of laboratory animals have led to the conclusion that DHPG is a prominent intraneuronal metabolite of NE and that DHPG formed in isolated tissues is derived predominantly from neuronal as opposed to nonneuronal sources (see reference 1 for review).
DHPG is present in plasma of humans (2, 3) at concentrations that generally are severalfold higher than those of NE. The source and meaning of DHPG in human plasma, however, are poorly understood. In the present study we examined how plasma DHPG reflects the rate and site of NE metabolism.
Plasma levels of the sympathetic neurotransmitter, NE, often have been used in clinical studies of cardiovascular and neuropsychiatric disorders as an index of sympathetic nervous system activity (4) . Plasma levels of NE are determined, however, not only by sympathetic nerve traffic but also by intraneuronal NE synthesis, presynaptic modulation of transmitter release into the synaptic clefts, neuronal reuptake (uptake-1), extraneuronal uptake and metabolism, the site of sampling, diffusion, and excretion. The limitations of measuring plasma NE alone to indicate sympathetic function are by now widely recognized.
In the present study, a recently developed liquid chromatographic-electrochemical assay technique for measuring simultaneously DHPG and catecholamines (2) was used to establish in humans whether plasma DHPG can reflect intraneuronal disposition of NE and provide information about sympathetic function unobtainable by measuring plasma NE alone.
Experimental approach
The experimental approach we used can most easily be understood by considering processes depicted in Fig. 1 . Catecholamine biosynthesis begins with uptake of the amino acid tyrosine into the sympathetic neuronal cytoplasm and conversion oftyrosine to dihydroxyphenylalanine by tyrosine hydroxylase and then to dopamine (DA) by L-amino acid-decarboxylase (5) . DA 
Predicted effects ofphysiological or pharmacological manipulations
This framework, based mainly on in vitro studies or studies of isolated, perfused organs, provided the basis for several hypotheses about plasma DHPG.
Stimuli that release endogenous NE, such as tilt or administration of the alpha-2 adrenoceptor antagonist, YOH, would be expected to increase plasma DHPG, whereas administration of the alpha-2 adrenocepter agonist, clonidine, would be expected to decrease plasma DHPG, because these manipulations would affect the amount of NE available for reuptake by uptake-1 and subsequent intraneuronal metabolism.
If NE recaptured after release were the main source of increases in plasma DHPG during sympathetic stimulation, then blockade of neuronal uptake would block stimulation-induced increments in plasma DHPG. Thus, in subjects pretreated with DMI, which inhibits uptake of NE into sympathetic nerve terminals, increments in plasma NE produced by
Methods

Subjects
The clinical data base was derived from assays ofplasma samples from subjects who had previously participated in studies involving plasma catecholamine pharmacokinetics or responses to stimuli known to affect sympathetically mediated release of NE into the circulation (6) (7) (8) (9) (10) 
CLONIDINE
Eight subjects, two hypertensive and six normotensive, six men and two women, age 22-38-yr old, had supine antecubital venous blood samples drawn via an indwelling catheter or needle at baseline and at 1, 2, 3, and 3.5 h after oral administration of 300 jg clonidine.
DMI
Five normotensive men, age 22-24-yr old, had supine antecubital venous samples drawn via an indwelling catheter or needle at baseline and at 1, 2, and 6 h after oral administration of 125 mg DMI.
Assay procedures
To conduct the studies reported here, we developed and validated a liquid chromatographic-electrochemical method for quantifying simultaneously plasma levels of DHPG, the catecholamine precursor dihydroxyphenylalanine, and the catecholamines. The method was described in detail previously (2) . Briefly, after addition of an internal standard (dihydroxybenzylamine) to the plasma, the catechols were extracted by absorption on alumina. After elution from the alumina, they were separated by reversed-phase, ion-pairing liquid chromatography and quantified by the current produced upon exposure of the column effluent to a series of oxidizing electrodes and then a reducing electrode. The limit ofdetection was -15 pg/ml for DHPG and -10 pg/ml for the catecholamines. Intra-and interassay coefficients ofvariation were 5.9% and 10.1%, respectively, at mean plasma DHPG concentrations of 992 and 924 pg/ml. The correlation for the scatter plot relating calculated plasma DHPG and DHPG added as an external standard was 0.99. The recovery of DHPG averaged 71% ofthe recovery of the internal standard, dihydroxybenzylamine, whereas the recovery of NE averaged 99% of the recovery of the internal standard. Concentrations ofDHPG were adjusted for this difference by using the recovery of DHPG in an extracted mixture of standards during each assay of samples. from baseline), whereas arterial DHPG averaged -1,000 pg/ml (-a 1.5-fold increase from baseline), t = 3.20, P < 0.01 for arterial DHPG). In subjects pretreated with DMI, plasma NE concentrations associated with given pressor responses were markedly smaller than those for the same pressor responses in untreated subjects (Table II) . Subjects pretreated with DMI had no change in plasma DHPG during intravenous infusion of NE (Table I) .
Data analysis
Clonidine
Oral administration of clonidine decreased plasma DHPG significantly (Table I ). The decreases in plasma DHPG occurred over about the same time course as decreases in plasma NE (Table II) and were statistically significant by 2 h after drug administration (t = 4.00, P < 0.01). In contrast with the results for NE infusion, during stimuli affecting release of endogenous NE (tilt, YOH, clonidine), the mean change in plasma NE was associated with a similar mean change in plasma DHPG (Fig. 4) . As indicated in Fig. 5 , plasma DHPG generally paralleled plasma NE during stimuli affecting release of NE. When plasma NE was markedly sup- ministration ofthe alpha-2 adrenoceptor antagonist YOH and similar absolute decreases, after oral administration of the alpha-2 adrenoceptor agonist clonidine. The present findings are in agreement with those of others involving measurements of plasma DHPG in humans or laboratory animals (3, (11) (12) (13) (14) (15) (16) (17) (18) (19) . Whereas similar changes in NE and DHPG during altered release of endogenous NE have led others to conclude that simultaneous measurement of plasma DHPG and NE does not offer important advantages over NE alone in the assessment of sympathetic function (19) , the results reported here about effects of neuronal uptake blockade lead to a different conclusion. Inhibition of uptake-1 exaggerated NE responses, but abolished DHPG responses to YOH, resulting in dissociation of DHPG responses from NE responses. This suggests that plasma DHPG reflects intraneuronal metabolism of NE, because if increments in plasma DHPG derived extensively from extraneuronal tissues, then during release of endogenous NE, inhibition of uptake-1 would have been expected to increase, not decrease, plasma DHPG.
If plasma NE alone were used to indicate sympathetic activity, then exaggeration of YOH-induced increments in plasma NE during uptake-I blockade could have led to the inference that DMI enhances the stimulatory effect of YOH ANEa (pg/ml) The same considerations apply to the interpretation of hemodynamic responses to exogenously administered NE during uptake-l blockade. The shift to the left in the pressor-log arterial NE concentration relationship during uptake-l blockade could have indicated that uptake-l blockade affects responsiveness of vascular smooth muscle to exogenously administered NE; however, this would not explain the lack of effect of NE infusion on plasma DHPG during uptake-l blockade, a finding that is more consistent with increased delivery ofexogenously administered NE to postsynaptic alpha-adrenoceptors. Therefore, simultaneous measurement of plasma DHPG and NE provided information about the cause of pressor hyperresponsiveness to exogenously administered NE that was not provided by measurement of plasma NE alone.
The effects of uptake-l blockade on plasma DHPG responses were similar to previously reported effects of uptake-l blockade on release of DHPG in isolated vascular beds (1).
Uptake-l blockade has been shown to abolish DHPG release and to enhance NE release during electrical stimulation of tissues preincubated with tracer-labeled NE (20) (21) (22) (23) . Similarly, inhibition ofuptake-I enhances stimulation-induced release of endogenous NE while decreasing endogenous DHPG release (24) . Thus, increments in DHPG release from tissue into incubation medium in laboratory animals and into plasma in humans appear to derive from recapture ofNE by sympathetic nerves.
During intravenous administration of NE at physiologically active doses, dose-related increases in plasma DHPG Dihydroxyphenylglycol in Humans 217 400 were observed. The increments in plasma DHPG were small compared with the NE concentrations, a pattern similar to that reported by lzzo et al. (12) . This would be expected from the large concentration gradient between NE in plasma and NE at neuroeffector junctions, where the drug could be taken up by uptake-l to provide substrate for DHPG formation. In subjects pretreated with DMI, no change in plasma DHPG was observed during NE administration. Although the NE concentration required to produce the same pressor response was much smaller in subjects pretreated with DMI than in subjects who were not, if plasma DHPG derived substantially from extraneuronal metabolism of NE, then the approximately ninefold increase in arterial NE during NE infusion still would have been expected to increase plasma DHPG (1, 25) .
The relatively small increments in plasma DHPG during NE infusions in the present study contrast with much larger percent increments in the study of Howes et al. (26) , who used tracer-labeled NE. Physiologically active doses of NE, as used in the present study, would be expected to stimulate arterial baroreceptor afferent activity and, because of reflexive sympathoinhibition, to attenuate DHPG responses; however, even using tracer-labeled NE we have failed to confirm the findings of Howes et al. On the basis of results obtained using a similar batch of tracer-labeled NE from the same manufacturer, we have suggested that the large increments in plasma radioactive DHPG reported in the study of Howes Source and meaning ofplasma DHPG under resting conditions One may hypothesize that although increments in DHPG during sympathetic stimulation may reflect intraneuronal production of DHPG, plasma DHPG under resting conditions may reflect extraneuronal production of DHPG from endogenously released or circulating NE. The present results do not exclude this possibility but do question it. If extraneuronal metabolism of endogenously released or circulating NE determined the basal levels of plasma DHPG, then clonidine administration, which caused marked suppression ofplasma NE, would have been expected to decrease DHPG to low levels, and NE infusions, which produced large-magnitude increases in plasma NE, would have been expected to produce largemagnitude increases in DHPG. Instead, substantial levels of plasma DHPG were observed after clonidine administration, and DHPG production was more pronounced during stimulation of endogenous NE release than during NE infusion, a finding that can be attributed to DHPG release from sites near neuroeffector junctions. The basal level of DHPG therefore probably did not result from extraneuronal metabolism of endogenously released or circulating NE.
Because of the small proportionate decrease in plasma DHPG after clonidine administration, one would predict that if NE release were suppressed completely, a plasma DHPG concentration of 700-800 pg/ml would be observed. In subjects treated with DMI at a dose previously shown to inhibit uptake-l effectively (9, 10), plasma DHPG decreased to a similar concentration range. These results, consistent with those of others about effects of clonidine or uptake-l blockade on plasma DHPG (12, (14) (15) (16) (17) (18) (19) (20) suggest that basal release of DHPG depends on a source other than NE recaptured by uptake-l. According to the model in Fig. 1, under conditions where uptake of endogenously released NE is very small, a substantial amount of DHPG could still be produced by leakage ofNE from intraneuronal storage sites. This would explain the finding that plasma DHPG decreased to a plateau concentration of -700-800 pg/ml after clonidine or DMI administration. This would also explain the finding of others that plasma DHPG has no diurnal variation (28) , in contrast with plasma NE. In fact, the rate of release of DHPG into the bloodstream under these conditions may provide an index of the net leakage of NE from the intraneuronal storage sites.
Whereas healthy subjects usually had an arteriovenous increment in plasma DHPG in the arm, patients who had undergone a regional sympathectomy had an arteriovenous decrement in plasma DHPG in the affected limb. This result suggests that release of DHPG into the bloodstream depends on intact sympathetic innervation.
In summary, since blockade of Uptake-l virtually abolished plasma DHPG responses to YOH or NE infusion, the above findings indicate that increments in plasma DHPG probably reflect intraneuronal production of DHPG from NE recaptured by uptake-l, and since substantial levels of plasma DHPG were observed even when endogenous release of NE was suppressed or when uptake-l was blocked, plasma DHPG under resting conditions appears to be derived mainly from intraneuronal leakage of NE from storage vesicles into the cytoplasm. Use ofplasma NE and DHPG to estimate NE concentrations at neuroeffector junctions We previously have provided evidence in humans that a large concentration gradient for NE operates between the neuroeffector junctions and the plasma (7) . By analysis ofblood pressure responses to NE infusions and endogenously released NE, we estimated that for a 20-mm Hg increment in blood pressure, the concentration of NE at the neuroeffector junctions would be -3 nM (-500 pg/ml). We also determined that NE concentration gradients between the plasma and neuroeffector junctions probably are reciprocal and equal.
Simultaneous measurement of plasma DHPG and NE responses during release of endogenous NE and NE infusion provides another means to estimate NE concentrations at neuroeffector junctions (or, more accurately, at uptake-1 sites). Fig. 6 depicts relationships between changes in mean arterial DHPG and changes in mean arterial NE during stimulation of NE release (YOH and three levels of tilt) and during NE infusion (three rates of infusion). For a given increment in the mean arterial level of DHPG, the arterial NE concentration was 1 l-log unit smaller for stimulation than for infusion, and the average NE concentration at uptake-1 sites must have been between the arterial NE concentrations for release and for infusion. Since the present results have implied that increments in plasma DHPG during NE release or NE infusion have the same source, uptake of NE by uptake 1, then given that the concentration gradient between the neuroeffector junctions and the plasma during NE release is the reciprocal of the NE concentration gradient during NE infusion, NE Thus, the increment in the cleft NE concentration for a given increment in the mean arterial level of DHPG would be half-way on a log scale between the increments in arterial NE for infusion and stimulation, (approximately at point X in Fig.  6 ). At an increment of -100 pg/ml in arterial DHPG, the estimated increment in cleft NE would be between -500 and 600 pg/ml. This value agrees well with values we previously reported in humans and rats (7, 29) . Since the NE concentration gradient between the plasma and the sites ofproduction of DHPG in the present study was the same as the previously reported NE concentration gradient between the plasma and the neuroeffector junctions, the results also are consistent with intraneuronal production of DHPG. Although a previous study indicated that the cleft-plasma and plasma-cleft concentration gradients probably are reciprocal and equal (29) , no experimental data are available to confirm or refute the assumed reciprocal gradients to and from plasma and uptake-1 sites.
DHPG/NE ratio and localization ofalterations in NE release or metabolism
Combined measurement of DHPG and NE at rest and during stimulation can provide clinical information about the release and intraneuronal disposition of the sympathetic transmitter. For instance, patients with pheochromocytoma generally have high plasma NE and slightly increased plasma DHPG, so that the NE/DHPG ratio is high (14, 30) . This would be expected if the tumor released NE into the bloodstream and the large plasma-cleft concentration gradient resulted in delivery of a small proportion of the circulating NE to neuronal sites of DHPG production. Because basal DHPG production normally far exceeds basal NE release, however, the plasma DHPG/NE ratio itself may not reflect accurately neuronal uptake or metabolism of NE at low rates of NE release.
The ADHPG/ANE relationship during alterations in endogenous NE release ofduring NE infusion would be expected to be shifted to the right in situations where uptake-1 is blocked, such as during treatment with tricyclic antidepressants or administration ofcocaine, or MAO is blocked, such as during treatment with a MAO inhibitor for depression. The ADHPG/ANE relationship would be expected to be shifted to the left when uptake ofcytoplasmic NE into storage vesicles is inhibited, as during administration of reserpine. Conclusions In conclusion, the present results indicate that plasma DHPG is derived from DHPG produced in sympathetic nerve endings; that intraneuronal production of DHPG depends on removal of released NE by uptake-l and leakage of NE from intraneuronal storage sites, the latter process predominating under basal conditions; that NE 
